+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 21Years - 70Years
All Genders
ID06848166

Evaluating Embolization Using SQUID 12 and SQUID 18 for Treatment of Chronic Resistant Migraine

Led by Vedanta University Clinic · Updated on 2026-09-11

30

Participants Needed

1

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of embolization of the middle meningeal artery MMA using non-adhesive materials SQUID 12 and SQUID 18 as a treatment for patients with chronic resistant migraine. This study aims to understand how this procedure impacts the number of migraine days over time in adults aged 21 to 70 who have experienced migraines resistant to other treatments. Participants receive total endovascular embolization of the frontal and parietal branches, and sometimes the occipital branch, of the MMA to reduce migraine symptoms. If the migraine pain is on one side, only that sides artery is embolized if on both sides, both arteries are treated. The procedure uses specific liquid embolic agents and is followed by a monitoring period lasting up to 12 months. During the study, participants track the number of migraine and headache days using diaries and scales over several intervals up to one year after the procedure. Researchers assess headache intensity, associated symptoms, and quality of life using standardized tools like the HIT-6 and MIDAS scales. Safety and changes in migraine frequency and severity are closely monitored throughout the year following treatment.

CONDITIONS

Brief Title

CHROnic Migraine Embolization

Research Team

A

Andrey E Petrov, MD, PhD

A

Andrey S Dakovskiy, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here